4.7 Review

Medicines use before and after comprehensive medicines review among residents of long-term care facilities: a retrospective cohort study

Journal

BMC GERIATRICS
Volume 22, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s12877-022-03187-0

Keywords

Medication review; Medication therapy management; Pharmacists; Drug utilization; Long-term care; Nursing homes; Residential facilities; Homes for the aged; Australia; Residential aged care

Funding

  1. Australian Association of Consultant Pharmacy (AACP)
  2. National Health and Medical Research Council (NHMRC) Early Career Fellowship [GNT1156439]
  3. Hospital Research Foundation Mid-Career Fellowship [MCF27-2019]
  4. NHMRC Investigator Grant [GNT119378]

Ask authors/readers for more resources

This study investigated the weekly trends in medication use before and after Residential Medication Management Review (RMMR) in Australian residential aged care facilities (RACFs). The results showed that the use of statins and proton pump inhibitors decreased after RMMR compared to those without RMMR. Decreased use of calcium channel blockers, benzodiazepines/zopiclone, and antidepressants were observed in the 3-6 and 6-12 months after RACF entry following RMMR provision. Negligible changes in antipsychotic use were observed in the 6-12 months after RACF entry following RMMR. No changes in the use of opioids, ACE inhibitors/sartans, beta blockers, loop diuretics, oral anticoagulants, or medicines for osteoporosis, diabetes or the cognitive symptoms of dementia were observed post-RMMR.
Background Residential Medication Management Review (RMMR) is a subsidized comprehensive medicines review program for individuals in Australian residential aged care facilities (RACFs). This study examined weekly trends in medicines use in the four months before and after an RMMR and among a comparison group of residents who did not receive an RMMR. Methods This retrospective cohort study included individuals aged 65 to 105 years who first entered permanent care between 1/1/2012 and 31/12/2016 in South Australia, Victoria, or New South Wales, and were taking at least one medicine. Individuals with an RMMR within 12 months of RACF entry were classified into one of three groups: (i) RMMR within 0 to 3 months, (ii) 3 to 6 months, or (iii) within 6 to 12 months of RACF entry. Individuals without RMMRs were included in the comparison group. Weekly trends in the number of defined daily doses per 1000 days were determined in the four months before and after the RMMR (or assigned index date in the comparison group) for 14 medicine classes. Results 113909 individuals from 1979 RACFs were included, of whom 55021 received an RMMR. Across all three periods examined, decreased use of statins and proton pump inhibitors was observed post-RMMR in comparison to those without RMMRs. Decreases in calcium channel blockers, benzodiazepines/zopiclone, and antidepressants were observed following RMMR provision in the 3-6 and 6-12 months after RACF entry. Negligible changes in antipsychotic use were also observed following an RMMR in the 6-12 months after RACF entry by comparison to those without RMMRs. No changes in use of opioids, ACE inhibitors/sartans, beta blockers, loop diuretics, oral anticoagulants, or medicines for osteoporosis, diabetes or the cognitive symptoms of dementia were observed post-RMMR. Conclusions For six of the 14 medicine classes investigated, modest changes in weekly trends in use were observed after the provision of an RMMR in the 6-12 months after RACF entry compared to those without RMMRs. Findings suggest that activities such as medicines reconciliation may be prioritized when an RMMR is provided on RACF entry, with deprescribing more likely after an RMMR the longer a resident has been in the RACF.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available